Results 1 to 10 of about 703 (80)

Фармакоэкономика туберкулезной инфекции у детей

Экспериментальная и клиническая фармакология, 2023
--
Natalia E. Usacheva, В. Е. Новиков, Т В Мякишева   +2 more
openalex   +3 more sources

Pharmacoeconomic comparison of the second generation insulin analogs and insulins on their base

Качественная клиническая практика, 2021
Effective control of Diabetes Mellitus (DM) is an actual task from clinical and economic points of view. The second generation insulin analogs increase level of DM compensation without hypoglycemia. The economic aspects of their usage have been evaluated
I. N. Dyakov, S. K. Zyryanov
doaj   +1 more source

Pharmacoeconomic characteristics of agonists of receptors for glucagon-like peptide-1 and medicines on their base

Качественная клиническая практика, 2021
The effective control of Diabetes Mellitus (DM) is an actual problem from optimal expenditures of health care system point of view. Agonists of receptors for glucagon like peptide-1 (aGLP-1) are one of the modern option for glycemia control in DM Type 2 ...
I. N. Dyakov, S. K. Zyryanov
doaj   +1 more source

Quantitative and qualitative evaluation of the use of nonsteroidal anti-inflammatory drugs in the Russian Federation over 10 years

Качественная клиническая практика, 2022
Relevance. Studies devoted to the assessment of consumption, as well as to the issues of pharmacosafety of nonsteroidal anti-inflammatory drugs, are limited at the national level in the Russian Federation.
G. I. Syraeva, A. S. Kolbin, S. A. Mishinova, A. A. Kalyapin   +3 more
doaj   +1 more source

Analysis Results of the Regional Registry of Patients with Diffuse Large B-cell Lymphoma: Risk Factors and Chemo-Immunotherapy Issues

Clinical oncohematology, 2019
Background & Aims. At least one third of patients with diffuse large B-cell lymphoma (DLBCL) are resistant to fi rst-line therapy. R-CHOP chemo-immunotherapy does not yield acceptable results in high-risk patients.
K. Kaplanov, N. Volkov, T. Klitochenko, I. Matveeva, A. Shipaeva, M. Shirokova, N. Davydova, E. Gemdzhian, DS Abramov, D. Konovalov, Gl Snigur, N. Red'kina, A. A. S. V. R. F. Diagnosis Polyclinic No., Samory Mashela str. Moscow Russian Federation Immunology   +13 more
semanticscholar   +1 more source

Hodgkin’s Lymphoma: Analysis Results of Volgograd Regional Registry

Clinical oncohematology, 2019
Background. The present paper discusses feasibility of fi rstand second-line therapies as well as the signifi cance of different risk factors in the population of all patients with newly diagnosed Hodgkin’s lymphomas (HL) in a 14-year period based on the
K. Kaplanov, N. Volkov, T. Klitochenko, I. Matveeva, A. Shipaeva, M. Shirokova, N. Davydova, E. Gemdzhian, A. A. S. V. R. F. Diagnosis Polyclinic No.   +8 more
semanticscholar   +1 more source

First-Line Treatment of Mantle-Cell Lymphoma: Analysis of Effectiveness and Cost-Effectiveness

, 2018
Aim. To study the correlation between effi cacy of mantlecell lymphoma treatment in clinical practice and failure of fi rst-line therapy and direct expenses depending on the fi rst-line therapy selection. Methods.
K. Kaplanov, N. Volkov, T. Klitochenko, A. Shipaeva, I. Matveeva, M. Shirokova, A. Proskurina, N. Red'kina, E. Gemdzhyan   +8 more
semanticscholar   +1 more source

Optimization of Epilepsy Pharmacotherapy Based on a Personalized Approach to Drug Safety Assessment

, 2018
Бочанова Елена Николаевна — к. м. н., доцент кафедры фармакологии и фармацевтического консультирования ФГБОУ ВО «КрасГМУ им. проф. В.Ф. Войно-Ясенецкого» Минздрава России. 660022, г. Красноярск, ул. Партизана Железняка, д. 1.
E. Bochanova, N. Shnayder, S. Zyryanov, S. Gusev, R. Nasyrova   +4 more
semanticscholar   +1 more source

Determination of the reference value of the incremental cost-efficacy and cost-utility coefficient in Russia in oncology

Качественная клиническая практика, 2018
The share of antineoplastic drug dossiers submitted to reimbursement in Russia raised from 15% in 2014 to 28% in 2017. The effectiveness and safety of innovative anti-cancer therapy is higher comparing to widely used traditional treatments.
A. S. Kolbin, A. A. Kurylev
doaj   +1 more source

An update of pharmacoeconomic analysis of trastuzumab emtanzine in patients with HER2+ breast cancer and central nervous system metastases

Качественная клиническая практика, 2019
Introduction. Regardless the pharmacoeconomic evaluation of trastuzumab emtanzine (T-DM-1) has been done before new data concerning T-DM1 effectiveness and also costs data require an update of pharmacoeconomic evaluation. Aim.
A. S. Kolbin, A. A. Kurylev, Y. E. Balykina, M. A. Proskurin   +3 more
doaj   +1 more source